Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AML
SAN DIEGO, Oct. 24, 2022 /PRNewswire/ -- Invivoscribe is pleased to announce that they have filed a supplemental Pre-Market Approval…